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Nanotechnology represents a set of methods and techniques, which allow the manipulation of 
matter on the atom-molecular scale, with the goal of creating radically new products and 
processes. It is well know that the materials in the nanoscale present unique chemical and 
electrostatic properties linked to a useful large surface of functionalization for molecular 
interactions or biologically relevant conjugates. Nowadays, the research is deeply focused on 
the translational applications of nanotools in medicine. In this context, nanomedicine appears 
as a new field of nanotechnological sciences based on the development of nanomaterials for 
biomedical investigation. At the same time, most nanomaterials are raising the attention of 
scientists thanks to the possibility of using them as therapeutic substitutes to improve current 
diagnostic agents or drugs. In terms of health safety, it is necessary to evaluate the chemical 
and physical properties of nanomaterials, in particular when they are synthesized for biomedical 
purposes. Nanomaterials, when carefully synthesized, remain stable preserving their unique 
nanoscale properties.  
 
In this work, a critical review has been performed to understand how nanotechnology has 
helped the fight against one of the most important human health conditions like breast cancer 
disease in the last nine years. In this review, it was highlighted that the purpose of scientists is 
to identify new nanomaterials that can be tolerated by biological environments displaying no 
toxic effects and their biocompatibility on cells.  
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Graphical abstract 1. Different nanomaterials developed against breast cancer. 
 
Before any translational application of nanotechnology in medicine, the critical step that can be 
done is represented by the evaluation of biological activity in in vitro studies. In this study, 
different nanomaterials were explored to counteract two important human health conditions, 
such as bone loss dysfunction and malaria, using in vitro experiments.  
In the first part of this work, a novel material with nano-mineralization is presented as a bone 
regeneration application to counteract the bone loss dysfunction. This problem has been 
reported during spaceflights missions connected to a significant bone loss inducing an 
osteoporosis like condition. In this context, the Random Positioning Machine (RPM) was 
applied to simulate long duration microgravity conditions (M, 0 x g). The osteogenic 
differentiation of human bone marrow-derived mesenchymal stem cells (hBM-MSCs) cultured 
on nanocrystalline magnesium-doped hydroxyapatite/type I collagen composite scaffold 
(MHA/Coll) has been investigated under simulated microgravity. Results indicated that the 
amorphous nanostructured apatite of MHA/Coll niche (3D culture) is able to promote the hBM-
MSCs differentiation in osteoblastic lineage in response to the transfer of key cues at the 
nanoscale to h-MSC in long-duration microgravity simulation.  
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Graphical abstract 2. Schematic diagram of MHA/Coll function in microgravity condition 
to counteract bone loss dysfunction. 
 
In the second part of this work, a novel nanomaterial is presented as an anti-malarial application 
in order to evaluate its anti-protozoal activity. Different silver nanoparticles obtained using 
Artemisia annua and Artemisia arborescens extracts were prepared by a “green” synthesis 
approach to assess their possible use as anti-malarial agents. The “green” AgNPs have thus 
been tested in Plasmodium falciparum infected red blood cells. Results evidenced a high anti-
malarial activity for A. annua-AgNPs in in vitro experiments against P. falciparum cultures 
compared to A. arborescens-AgNPs.  
 
In conclusion, considering the results gathered by the two nanotechnological applications here 
presented, it emerges that the use of nanomaterials has improved the osteoinductive potential 
of the scaffold and the antimalarial activity against P. falciparum.  
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Graphical abstract 3. Green synthesis of Artemisia-silver nanoparticles. 
 
Finally, data collected in vitro open a new path for further studies to investigate the potential of 
these nanomaterials as a possible new nanotechnological strategy against bone loss dysfunction 
and malaria diseases. 
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Chapter 1. Introduction 
1.1 Historical concept of nanotechnology 
Nanotechnology is defined as a novel approach to engineering of innovative materials and 
functional systems at the nanoscale, generally between 1 and 100 nanometers in size.  
The concept of “Nanotechnology” was introduced for the first time by Dr. K. Eric Drexler in 
the 1980’s, described as one of the most founding father of the nano science. In his work 
published in PNAS in the 1981, he outlined the ability to design protein molecules that make 
possible the construction of molecular machines.1 This molecular engineering underline the 
future development paths in molecular manipulation and nanotechnology applications.1 
Furthermore, in his book entitled “Engines of Creation: The Coming Era of Nanotechnology” 
(Drexler K. E., 1986), he described to a wide audience the importance of nanotechnology in the 
construction of molecular machines working on a molecular scale in order to manipulate matter 
from the bottom up.2 Drexler’s research in the field of application of advanced 
nanotechnologies has been the basis of “molecular nanotechnology” and physics-based analysis 
in “nanosystems” as “computation and molecular machinery”.3 In spite of the large part of 
science that is defined today as “nanotechnology”, the meaning of this word is not the original 
one. The primary term of “Nanotechnology” refers to engineering ability to design and 
construct nano-structures and devices using the bottom-up approach with atomic precision. This 
theoretical capabilities were predicted by the famous physicist Richard Feynman in 1959: “I 
want to build a billion tiny factories, models of each other, which are manufacturing 
simultaneously. . . The principles of physics, as far as I can see, do not speak against the 
possibility of maneuvering things atom by atom. It is not an attempt to violate any laws; it is 
something, in principle, that can be done; but in practice, it has not been done because we are 
too big”. — Richard Feynman, Nobel Prize winner in physics. 
 
 Elisabetta Avitabile, Nanotechnology: development of nanotools to counteract human diseases,  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
13 
Feynman’s vision of nano scale factories represents the main objective of the advanced 
nanotechnology using molecular machine systems.3 He was the first physicist who launched 
the challenged of molecular machines, collected by Jean Pierre Sauvage, Sir J. Fraser Stoddart 
and Bernard L. Feringa, the winners of the 2016 Chemistry Nobel Prize, during the famous talk 
in 1959 known as “There’s plenty of room at the bottom”.4  
1.2 Cultural perception of nanotechnology  
In the last decades, science history has observed the birth of new and innovative disciplines, 
which now influence the everyday life. Presently, the new disciplines like nanotechnology and 
nanomedicine are emerging as powerful applications aimed at improving the quality of life. It 
was described that the perception and correct scientific communication combined with public 
participation would have a significant impact on the greater growth of these new disciplines.5 
In the last decade, the concept of manipulation of matter at the atomic or molecular level and 
the possible use of nanotechnology in real life has given rise to a debate of a cultural nature. 
The concept of cultural conditions represents the tendency of people to base their cultural 
appraisal according to their factual beliefs of a probably dangerous activity.6 An interesting 
study has described the problem of the cultural cognition of the concept of risks and benefits 
related to the use of nanotechnology involving 1,862 Americans divided in 2 groups: no-
information condition and information-exposed condition.7 As reported in Figure 2, the results 
showed that information exposure does not have a relevant effect of probability that either a 
subject can perceive the benefits of nanotechnology to be greater than its risks (Figure 1a).7 
On the contrary, information exposure showed statistically significant impact on subject 
defined with reference relate to their cultural worldviews (Figure 2b).7  
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Figure 2. “Effect of information on risk–benefit perceptions of subjects defined by self-reported 
familiarity with nanotechnology and cultural worldviews. a) Likelihoods of response for the benefits 
of nanotechnology exceeding the risks in the no-information and information-exposed conditions when 
cultural worldviews are controlled (set to their means) for respondents who are unfamiliar (bottom line) 
and familiar (top line) with nanotechnology. b) Likelihoods of response across conditions when 
familiarity is controlled for (set to its mean) and the culture variables are set at values that reflect the 
worldviews of modestly hierarchical and individualistic subjects (top line), and modestly egalitarian 
and communitarian ones (bottom line). N ¼ 1,672. *Change in likelihood across conditions significant 
at P ≤ 0.05”, (Kahan et al., 2009). 
 
These findings suggest a model of how cultural predisposition and exposure to information 
about nanotechnology effects act on risk–benefit perceptions (Figure 3).7 
 
 
Figure 3. “Relationships between cultural worldviews, information exposure and risk–benefit perceptions. 
The study results suggest that cultural worldviews influence perceptions of the risks and benefits of 
nanotechnology both by influencing how likely subjects were to be exposed to information (or report being 
exposed to information) about nanotechnology, and by determining what effect—positive or negative—they gave 
to that information”, (Kahan et al., 2009). 
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Several works published in Nat. Nanotechnology have reported that analyzing various risk 
nanotechnology perception surveys, people are able to perceive more benefits than risks8 and 
that non experts are more concerned with nanotechnology risks compared to scientific 
community7, 9, 10 Basically, people who have a protechnology cultural orientation are thus more 
likely to draw positive conclusions related to nanotechnology contrary to individuals who lack 
that predisposition, showing a high probability that they can react negatively.7 Many 
researchers have highlighted the possibility that spontaneous and continuous scientific 
information can play an important role on the public opinion on a balanced conception of the 
risks and benefits of nanotechnology.7-11 In general, public perception of nanotechnology 
applications is basic for their realistic growth in everyday life. Nowadays, several pilot study 
have shed light on the positive public’s perception of nanotechnology, due to the high interest 
for science and technology.11-13 Furthermore, several websites and social networking services 
could offer advantages for knowledge sharing, promoting the fast science dissemination 
compared to the traditional methods.14  
1.3 Manufacturing at the nanoscale 
The world of nanotechnology acting directly on the natural connections between atoms, 
represents a future perspective of new materials through the assembly of atoms and molecules 
in an automatic way, as happens in the living world.15 In this context, the goal of 
nanotechnologists is therefore to manipulate the matter at the nanometer scale to build new 
materials and products with special physical and chemical characteristics, better than existing 
materials.16 The great success of matter manipulation is to be found in the excellent properties 
shown by the nanomaterials compared to the bulk structures.17 It is well known that when the 
particle sizes are getting close to the nanometer they acquire new properties and just for this 
reason, it is necessary to revaluate the current knowledge under such a new perspective.17  
It has been observed that while approaching the nanoscale size, the percentage of surface atoms 
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increases considerably, which are often much more reactive than the atoms located inside the 
particle.17 Accordingly, as the particle size decreases, its surface area increases. Furthermore, 
thanks to the knowledge of the fundamental properties up to the atomic or molecular scale, 
nowadays it is possible to design "artificial materials" with excellent properties according to 
the prefigured application.18, 19  
There are two main ways to create nano structures: 
- the "top down" approach which consists in reducing the size of the smaller structures using 
physical methods; 
- the "bottom up" approach allows starting from small components, normally molecules or 
atoms, to realize nanostructures both of inorganic and organic type. 
The first approach guarantees better results in terms of reproducibility, however it requires the 
use of special and often expensive equipment.20 On the contrary, the second approach leads to 
higher performances under many points of view, because by starting from solutions in liquid 
phase, at controlled temperature and pressure, it allows to regulate factors as shape and 
dimensions of the nanomaterials, for instance. However, the latter approach requires a 
knowledge and a very fine control of the synthetic protocols, which has not yet been completely 
achieved.21  
In general, the matter on earth, under the impulse of self-regulating forces, has assumed 
complex shapes over the course of billions of years. The possibilities of application of living 
matter are sometimes limited, because of its low stability and toxicity in biological 
environments.  
The goal of nanotechnologies is based on the creation of artificial nanostructures able to 
withstand much more aggressive operating conditions, such as extreme acidity / basicity or 
temperatures of hundreds of degrees, high stability and biocompatibility. Furthermore, the 
creation of nanostructures and the possible future use of nanoparticles in the field of science 
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will result in the introduction of nanotechnology into daily life without radical changes. In 
general, today the revolutionary "Nano-science", among the various sectors in which it has been 
introduced, finds its application above all in the biomedical field, but it is also very developed 
in physics/chemical science and in the environmental field to look for a solution against 
pollution.  
1.4 Nanotechnology application in medicine 
The recent advances in nanoscale science and engineering have led to the application of 
nanotechnology in medicine with the development of new biomedical nanotools.22 Besides 
industry and combinatorial chemistry applications, nanomaterials have been explored for future 
nanomedicine therapy.22 Manipulation with macromolecular and molecular precision have led 
to the manufacture of innovative nanomaterials, which are able to interact with and often mimic 
biological systems.23 In particular, nanotechnology can create human-made materials in the 
nanoscale range, the same scale where cellular and biological processes take place.24 The 
potential adverse toxicity, biosafety and clinical opportunity of nanotools should be evaluated 
carefully in ex vivo preclinical models before any application in the human body. Precisely 
nanoparticles, nanostructured tissue scaffolds and nanobiomaterials, overcoming the limitation 
found in conventional agents, have been investigated for the development of alternative 
therapeutic treatment for human diseases.25, 26 Over time, nanomedicine have found its primary 
application in the treatment of several serious human conditions including cancer and 
metastases, allergies, viral and microbial infections, bone resorption and brain disorders.  
Nowadays, cancer represents a global health problem related to an uncontrolled malignant cells 
proliferation that overcrowd normal cells around in the body.27 Until now, cancer 
nanotechnology represents a new field of science focusing on the use of nanomaterials for 
enhancing cancer detection, treatment and diagnosis through the development of new nanotools 
to be applied in oncology.28, 29 Cancer nanotechnology has demonstrated excellent approaches 
 Elisabetta Avitabile, Nanotechnology: development of nanotools to counteract human diseases,  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
18 
to cancer detection, diagnosis and treatment with limited toxicity compared to the traditional 
cancer therapy.30, 31 One of the most important aspects of cancer nanotechnology represents the 
ability to engineer nano carriers with multiple molecules that, because of their small size, can 
penetrate tumors with high specificity, consequently with significantly fewer side effects.32-34 
Moreover, nonsurgical tumor ablation techniques have been developed with the complete 
destruction of tumor cells by the direct application of thermal and chemical therapies using 
nanomaterials, composed of metals, lipids, or polymers.35 To this end, during the last years, 
nanotechnology approaches have provided innovative promising strategies in order to 
efficiently detect and treat cancer and metastatic conditions.36 The importance of 
nanotechnology in drug delivery application is addressed to the ability of molecular structure 
manipulation in order to create nanotools directed towards programmed target.37 Of particular 
interest, manufacturing at the nanoscale has accelerate the development of nanoparticles 
complexes to improve the drug loading with precision, helping the possibility to become a real 
medical strategy.38,39 In this context, nanomaterials can be designed to transport 
chemotherapeutic drugs directly to the tumor cells using specific antibodies to target the cancer 
site.40 Anyway, before initiation of cancer treatment, it is essential to carry out diagnostic 
imaging procedures to understand the type of cancer lesion. In this context, a new field of 
nanomaterials as theranostic agents is emerging, which are able to combine diagnostic and 
therapeutic strategies into one procedure.41  
In the last years, the scientific community is aiming to investigate the properties of 
nanoparticles-based biological molecules to induce stem cells proliferation in damaged tissue 
like bone, liver, spinal cord and heart, for regenerative medicine applications.42-44 On the other 
hand, for human diseases based on bacterial or parasitic infections, scientist are pointing their 
attention towards metal nanomaterials.45,46 Metal nanoparticles and in particular silver 
nanoparticles have been studied as antibacterial agents, and they could be used to counteract 
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viral or parasite human infections.47, 48  
Indeed, thanks to their dual properties of drug delivery and imaging together, their unique 
properties make the metal nanoparticles a possible future candidate against human infections. 
Nevertheless, the risks connected to the presence of nanomaterials inside the human body 
should be balanced with their beneficial aspects in the field of nanomedicine application. 
However, an increased knowledge of nanotools mechanism effects will provide new less toxic 
therapies with safer nano-complex to specifically treat human diseases.  
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Chapter 2. Aim of the thesis 
Recent advances in technology and engineering have led to the application of nanotechnology 
in medicine with the development of new nanoscale biomedical systems. Nowadays, 
nanotechnology could represent one of the best promises to develop new therapies in medicine. 
Compared to traditional diagnostic agents or drugs, nanomaterials can be engineered to improve 
multiple functions in a single system. Moreover, in the recent years, large varieties of 
nanomaterials have been investigated for the control of drug release and gene therapy being of 
hope for the next generation treatments in the near future. However, despite the still limited 
results on the non-toxic effect of nanomaterials, the main step before any biological application 
is represented by their safety assessment. For all these reasons, scientists are researching new 
less toxic nanotools for new diagnostic strategies.  
 
This thesis aims to shed light on the possibility of using innovative nanomaterials as future 
therapeutical agents. The research work consists of three parts that include several innovative 
nanotechnology applications to counteract three types of serious human diseases. The purpose 
is to present new nanoscale solutions to develop nanotools able to fight human health problems. 
In this work, breast cancer, bone loss dysfunction and malaria have been taken into 
consideration as they represent three of the most studied human diseases in recent years. 
In the first part of this work, breast cancer (BC) has been taken into consideration because it 
represents one of the most common types of cancer affecting women (and in fewer cases also 
men) worldwide. BC is one of the most studied tumors as it is considered one of the most 
aggressive forms of cancer and is the second leading cause of death in the world. In this 
perspective, a broad review of the current research on BC was necessary in order to point out 
what are the most promising nanomaterials that can perform a breakthrough revolution in the 
scenario of breast cancer for diagnosis, therapy and theranostics. It was thus necessary to 
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examine an extremely vast amount of works carried out in the last few years related to 
nanotechnology approaches against BC and discuss all the specific potentialities of the 
nanotechnology tools to overcome current diagnostic barriers, reduce side effects during cancer 
treatment and toxicity on healthy tissues.  
 
In the second part of this work, bone loss has been taken into consideration because it represents 
one of the major age-related health problems, causing bone dysfunction and fractures that 
significantly impair the quality of life. In this context, it has been reported that also spaceflights 
lead to dysregulation of the osteoblast function connected to a significant bone loss inducing 
an osteoporosis like condition. The bone loss dysfunction under microgravity conditions (MG) 
is related to an impairment of osteoblast and an increase of bone resorption with a significant 
decrease in osteogenic gene expressions, which are ordinarily connected to a normal bone 
resorption. The purpose of this work was to perform an integrative study evaluating the effect 
of simulated microgravity on human bone marrow-derived mesenchymal stem cells (hBM-
MSCs) cultured in nanocrystalline magnesium-doped hydroxyapatite/type I collagen composite 
scaffolds (MHA/Coll) to promote the osteogenic differentiation. In this study, the potentiality 
of nanostructured MHA/Coll scaffold (3D culture) to hinder osteoblast dysfunction under long 
duration simulated microgravity, as osteoporosis like condition is discussed. 
 
Finally, in the third part of the work, malaria has been taken into consideration because it 
represents one of the most common infectious disease and one of the most serious public health 
problem worldwide. In this context, metal nanoparticles have been given increasing interest in 
the scientific community due to their chemical stability and biological activity against bacteria 
and parasites. Moreover, silver nanoparticles (AgNPs) could represent new nano-tools for 
biomedical applications thanks to their promising antibacterial properties. The purpose of this 
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work was to perform the synthesis and characterization of different types of silver nanoparticles 
(AgNPs) using a “green synthesis” approach, and to assess their potential antimalarial efficacy. 
In this study the hemocompatibility and the antimalarial activity of such AgNPs against malarial 
parasite Plasmodium falciparum is also discussed. 
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Chapter 3. Literature review: nanotechnology and breast 
cancer  




BC represents a malignant tumor where breast cells grow out of control and overcrowd normal 
cells. BC represents the most common type of cancer affecting women worldwide, and it is the 
second leading cause of death in the United States with 253 000 new cases estimated in 2017.1 
When BC occurs, it is crucial, for the prognosis, to achieve early detection, followed by 
opportune treatments including surgery and chemotherapy. Nowadays, the most important 
clinical analyses comprise mammograms, ultrasound examinations, and nuclear magnetic 
resonance imaging (MRI). Moreover, biopsy and blood chemistry studies help for a more 
accurate diagnosis of BC. Around 4.9 million breast biopsies are performed every year in the 
world, and 3.2 million of them are checked for screen detection of non-palpable breast lesions, 
of which a third are found to be malignant.2 However, by considering the current methods of 
BC diagnosis, any doctor can ensure a survival rate close to 100%. On the other hand, if one 
focuses on BC therapy, many current treatments are invasive, involving several breast biopsies, 
wire-guided localization, and eventually surgical removal. All current treatments including 
chemotherapy and prophylactic strategies are disfiguring, invasive, and associated with 
significant side effects.3 
For all these reasons new diagnostic strategies and new effective and less toxic therapies are 
urgently needed. The recent advances in technology and engineering have led to the application 
of nanotechnology in medicine with the development of new nanoscale biomedical systems.4 
Nanomaterials have been explored for biomedical research because of their extraordinary 
physicochemical characteristics. In particular, cancer nanotechnology has proposed excellent 
approaches to cancer detection, diagnosis, and treatment with limited toxicity compared to the 
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traditional cancer therapy.5 In this context, nanotechnology can create human-made materials 
in the nanoscale range, the same scale where cellular and biological processes take place.6 The 
major potential of cancer nanotechnology includes the possibility to engineer nanovehicles with 
multiple molecules that, because of their small size, can penetrate tumors with high specificity, 
consequently with significantly fewer side effects.7-9 Furthermore, techniques for nonsurgical 
ablation of tumors have been developed, leading to the complete destruction of tumor cells by 
the direct application of thermal and chemical therapies using nanomaterials, composed of 
metals, lipids, or polymers.10 Therefore, cancer nanotechnology brings in the scenario of BC 
oncology huge expectations, and nanomaterials can be adapted for the different BC forms and 
disease status. Because of the high degree of control, the characteristics of human-made nano-
tools can ensure new perspectives. Nanomaterials in BC can act as: i) drug nanocarriers, ii) 
nanodiagnostic tools, and iii) theranostic tools. 
Regarding drug delivery, nanomaterials can be designed to transport chemotherapeutic drugs 
directly to the breast cells using specific antibodies to target the cancer site.11 Doxorubicin 
(Dox) linked to nanomaterials is the most investigated drug for cancer therapy. Very recently, 
the group of Ferrari has described an injectable nanoparticle generator (iNPG), consisting of a 
discoidal micrometer-sized particle that can be loaded with Dox conjugated to poly(L-glutamic 
acid) (pDox).12 Intravenously injected iNPG-pDox accumulates in the tumor region and shows 
enhanced efficacy in mouse models of metastatic BC. 
In the context of the development of diagnostic tools, there are many successful examples of 
nanomaterials applied to visualize BC [e.g. superparamagnetic iron oxide nanoparticles 
(SPIONs) and magnetic nanoparticles (MNPs)]. Different studies have reported a sensitivity of 
73-100% and a specificity of 92-98% in the lymph nodes using SPIONs.13 Among other 
advantages, SPIONs are useful for the early detection by MRI, displaying also a good immune-
compatibility and echogenic properties.14 Today other nanotechnology-enabled systems are 
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under clinical trials. For example, [18F]-FAC isodeoxycytidine analogue for deoxycytidine 
kinase (DCK) labeled with fluorine 18F, was proposed as a novel PET imaging probe.15 
Nanoparticle MRI contrast agents that bind the αvβ3-intregrin, expressed on the surface of the 
newly developing blood vessels associated with early tumor growth, were realized.16 
Lymphotrophic superparamagnetic nanoparticles developed by the MIT-Harvard Center for 
Cancer Nanotechnology Excellence (CCNE) were used to identify small, otherwise 
undetectable, lymph node metastases.16 
Before initiation of a cancer treatment, it is essential to carry out diagnostic imaging procedures 
to understand the type of cancer lesion. In this context, theranostic agents can combine 
diagnostic and therapeutic strategies into one procedure.17 Hosoya H. et al.18 described a 
hydrogel-based nanoplatform conjugated with Dox that enables ligand-directed tumor targeting 
and multimodal imaging. The data obtained using this strategy suggest that targeted hydrogel 
photothermal therapy represents a functional theranostic clinical application such as image-
guided approaches for diagnostic and therapeutic monitoring. Many carbon based 
nanomaterials have been studied for medical applications such as tissue engineering, drug 
delivery, and gene transfection explaining their potential as molecularly-targeted and dual-
modality imaging agent.19 
In this Review, the purpose was to point out what are the most promising nanomaterials that 
can perform a breakthrough revolution in the scenario of BC.  
A thorough overview of nanomaterials that have been so far investigated against BC, analyzing 
the most interesting publications present in the literature, has been carried out. The applications 
on drug delivery, imaging, and theranostics have been scrutinized and all specific potentialities 
of the nanotechnology tools to overcome current barriers, to reduce toxicity, and to avoid 
suffering from anticancer treatments have been discussed, in order to shed light on the 
challenges and hope offered by the different nanomaterials in the treatment of BC.  
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3.2 Overview and study selection criteria  
Initially, three main nanomaterial applications for BC have been analyzed in details: i) drug 
delivery, ii) imaging, and iii) theranostics. 
For this analysis, a PubMed search was performed using the following keywords: breast cancer, 
nanotechnology, nanomedicine, nanoparticles, nanomaterials, drug delivery, theranostics, and 
imaging. Keyword searching was also performed in different combinations. High impact 
review articles served as additional tools. The list of reported studies includes all retrieved 
publications from 2009 to December 2017. A full and deep characterization of all applications 
was carried out based on type of materials, conjugated drugs, imaging modialities, applications 
other than imaging, model, type of species examined (human, mouse and their combination), 
other types of cancer other than BC.  
Figure 1 presents the number of publications over the years, the types of applications on 
therapy and diagnosis and the types of species examined in the cited works. 
 
Figure 1. Status of applications used on BC studies. A) Analysis of publications in the last 9 years (2009 to 
2017). B) Relative percentages of publications for imaging, theranostic and drug delivery applications. C) Species 
examined in each publications (human, mouse and combination of human and mouse). 
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The trend, from 2009 to December 2017, indicates an oscillating tendency in the studies on BC 
(Figure 1A); e.g., the number of retrieved publications in 2011 was 1.5 higher compared to 
2009. After a clear decrease in 2012, the state of publications in all the following years was 
higher than 2009. Imaging is the first application (58%), while 35% of the articles referred to 
theranostic applications combined with drug delivery (Figure 1B). Besides, drug delivery, a 
single application, is reported in 7% of the studies. In Figure 1C the relative percentage of 
publications describing human cell lines (in vitro and ex vivo), mice (in vivo, vitro, and ex vivo), 
or both has been shown. Although there are not many differences in the percentage of 
publications of the examined species, it was evident that the majority of the studies has been 
carried out in humans cells (39%), 28% in mice, and 33% in both of them. International 
variations in BC incidence rates reflect differences in the availability of early detection tools as 
well as risk factors.20 In this context, the countries where BC studies were carried out have been 
analyzed, taking into consideration the affiliation of the corresponding author (Figure 2). 
 
 
Figure 2. Percentage of publications carried out on nanomaterials fight against BC per Countries.  
The piece of the cake in yellow reported the studies in a percentage of <2 % conducted in other countries such as: 
New Zealand, Greece, Brazil, Taiwan, Malaysia, Riyadh-Saudi Arabia, The Netherlands, Israel, Germany, France, 
Georgia, Poland. 
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It emerged that the majority of the studies (39%) were conducted in USA, 26% in China, 5% 
in South Korea, 4% in Japan, Singapore and India, 3% in UK, 2% in Canada, Italy, Iran and 
Australia; very few studies were conducted in other countries (< 2%). By the analysis of these 
percentages, it was possible to conclude that there is no correlation between countries and 
incidence of BC. In fact, considering countries like United States where there is a high number 
of scientists, it is obvious to expect a larger amount of published studies. A careful analysis of 
these data showed that there is not a strong correlation between the number of studies published 
and the relative incidence recorded. More developed countries represent about one-half of all 
BC cases with 38% of mortality. In fact, as reported in the pie graph (Figure 2), USA, China, 
South Korea have the highest percentage of studies compared to the other countries, but it was 
estimated that the higher mortality from BC occurs in Asian countries, as Qatar, India and Iran. 
Since BC may lead to metastasis in other regions of human body, many scientists focused at 
the same time on other cancer forms together with BC. Thus, many authors studied the BC-
specific ligand/cell surface also identified in other type of cancers, or BC overexpressed 
receptors using other cancers as negative controls. Therefore, other types of cancer investigated 
with BC have been also reported (Figure 3).  
 
Figure 3. Percentage of publications focusing on other types of cancer together with BC. 
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Lung cancer was studied in 22% of the papers, pancreatic and prostatic cancer in 19% of the 
papers, and ovarian cancer in 13%. Melanoma, colon and liver cancers were studied in 6% of 
the publications and the other types of cancer including gastric cancer, glioblastoma and bone 
cancer were studied in 3% of the cases (Figure 3). 
3.3 Drug Delivery 
Drug delivery is a key nanotechnology application. This type of application alone is reported 
in only the 7% of the cases considered. Indeed, in many examples, drug delivery applications 
refer to theranostic applications (corresponding to 35% of the studies). Analyzing the different 
publications, it emerged that several types of drugs are used in drug delivery or in combination 
leading to theranostic nanomaterials (Figure 4). 
 
 
Figure 4. Conjugated drugs to nanomaterials. Number publications in the last 9 years based on the type of drugs 
conjugated to nanomaterials and nanoparticles against BC. 
 
These drugs comprise Dox, herceptin, paclitaxel (PTX), dextran, curcumin, mitoxantrone, 
tamoxifen, methotrexate, pentoxifylline, and docetaxel. Dox represents the most important 
anticancer chemotherapeutic drug.21 Indeed, its ability to intercalate DNA bases, inhibiting the 
topoisomerase II enzyme during DNA transcription, was widely demonstrated.22 Many studies 
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used nanomaterials conjugated with Dox as an innovative cancer therapy.22-27 Herceptin was 
used for the treatment of metastatic BC, thanks to its properties of blocking cell proliferation.28-
33 Recently, Wang et al.34 reported a synthesis of a particular multifunctional anti-cancer 
complex based on functionalized magnetic nanoparticles (MNPs) and quantum dots (QDs) with 
a dual-drug combination. In detail, PTX/MNPs/QDs@Biotin–PEG–PCDA nanoparticles have 
shown a high uptake by BC cells (MCF-7/ADR) and good drug release. These nanoparticles 
are able to combine various proprieties useful for imaging (QDs), targeted delivery and uptake 
(MNPs), and dual drug treatment using two drugs (e.g. PTX and curcumin). Curcumin, a natural 
compound extracted from Curcuma longa, helped to obtain a high PTX accumulation in the 
tumor target and induced a down-regulation of drug efflux transporters. Moreover, PTX has 
shown excellent efficacy in a wide spectrum of cancer treatments, but its formulation has led 
to serious side effects in patients, as neurotoxicity, nephrotoxicity and allergic reaction. 
Modified PTX as nanomicelles was developed to overcome these obstacles and multidrug 
resistance.35 
Zhao et al.36 described hybrid paclitaxel nanocrystals that integrated fluorescent molecules for 
therapy and imaging in a breast tumor. The authors observed a more efficient anticancer effect 
of this system in mice with breast tumor than in mice treated with pure PTX. The hybrid PTX 
nanocrystals have shown the ability to easily accumulate in the tumor area following 
intravenous administration. Others described PTX release directly into the tumor sites for 
theranostic nanomedicine application 34-37 and drug delivery.38 In the third position of the most 
important drugs used against cancer there is curcumin, a compound endowed with interesting 
properties including an anti-inflammatory action.39 Curcumin can specifically modulate the 
expression of proteins in proliferating cells, in adhesion and in migration, and it is used as an 
anticancer drug to prevent metastatic formation or to limit cancer progression.40, 41 Furthermore, 
other types of drugs such as dextran33, 42, 43 or docetaxel44, 45 were loaded onto nanoparticles for 
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cancer detection, while mitoxantrone,46 tamoxifen,47 methotrexate,48 pentoxifylline,49 
docetaxel,50, 51 cisplatin and gemcitabine were combined for the development of theranostics 
materials.52 Recently, the group of Chan provided quantification of the delivery efficiency of 
nanoparticles at the tumor site. The authors reported a bombshell work whose meta-analysis 
suggested that very few "targeted" nanoparticles reach the target. According to this analysis, 
only 7 out of 1000 engineered nanoparticles are able to accumulate into the tumor in vivo.53  
3.4 Imaging 
Nowadays, nanotechnology based on imaging represents a very promising solution for non-
invasive investigations of cancer lesions. We found that in 58% of the examined studies the 
first approach against BC is based on the use of nanotools for imaging (Figure 1B). Breast 
imaging can be undertaken using MRI, the most commonly available modality, thanks to its 
rapidity and high resolution 54(Figure 5A). 
 
Figure 5. Overview on different types of techniques and nanomaterials for imaging.  
A) Analysis of the number of publications based on the different kind of Imaging Applications for BC.  
B) Types of nanomaterials used for imaging. 
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Different nanoparticles with appropriate surface modification have been used in vivo as MRI 
contrast agents because of their high magnetization and nano-size.55 In particular, the surface 
coating was exploited to create non-toxic and biocompatible nanomaterials.56-78 For example, 
Medarova et al.79 have modified SPIONs with Cy5.5 dye and conjugated them to specific 
peptides. This tumor-specific contrast agent was able to successfully target the under-
glycosylated MUC-1 (uMUC-1) tumor antigen, present in over 90% of the cases of BCs. 
MRI is followed by two other techniques, namely fluorescence imaging (FI)5, 64, 78, 80-119 and 
confocal laser scanning microscopy (CLSM) (Figure 5A).58, 64, 67, 73-75, 120-134 Both of them have 
shown to be excellent imaging tools for many in vitro studies on murine and human cancer 
cells. Pan et al.120 described in vitro cancer detection of human cells (MCF-7) using fluorescent 
quantum dots (QDs) as luminescent probes for targeted imaging. The authors described a new 
strategy to prepare QDs formulated in folate-decorated nanoparticles (PLA-TPGS/TPGS-
COOH) (PLA-TPGS, poly(lactide)-D-α-tocopheryl polyethylene glycol succinate) for BC 
detection and diagnosis at its early stage. They demonstrated that functionalization with a 
copolymer was able to improve imaging sensitivity with reduced side effects on normal cells. 
Another imaging technique used in BC studies is the near-infrared (NIR) optical imaging, 56, 79, 
83, 96, 97, 99, 107, 112, 127, 132, 135-143 which represents the fourth most exploited type of modality in the 
total of the examined studies. Through NIR fluorescence images, the authors analyzed directly 
in vivo the biodistribution of many nanomaterials in different organs and their elimination. 
Bardhan et al.56 used modified gold nanoshells (AuNSs) with fluorophores to enhance the 
fluorescence in live mice grafted with human cancer cell lines over 72 h. The nanocomplex, 
conjugated with specific antibodies to target human epidermal growth factor receptor 2 (HER2) 
overexpressed in BC, provided significant information regarding the distribution of 
nanomaterials, and represents a new approach for cancer therapy and non-invasive treatment 
for soft-tissue tumors.56 
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Moreover, it was found that computed tomography (CT)70, 113, 139, 144-152 is at the fifth position 
in terms of number of studies related to BC, while other techniquews are less used, including 
superconducting quantum interference device (SQUID),94, 153 surface enhanced Raman 
scattering (SERS),81, 154-159 synchrotron X-ray micro-imaging (X-ray),150, 152, 160, 161 positron 
emission tomography (PET),106, 115, 142, 162 and fluorescence molecular tomography (FMT).70, 73 
Single-photon emission computed tomography (SPECT),163 ultrasound imaging (US),71 
intermolecular quantum coherence (iMQC),164 optical coherence tomography (OCT),165 
ultrashort echo time (UTE)166 are in the last positions as imaging techniques used (Figure 5A). 
Focusing on the imaging tools, it emerged that the first most studied nanomaterials are SPIONs 
(Figure 5B).  
Many publications have shown the interesting potential of SPIONs for tumor detection, cancer 
therapy and drug delivery.13, 54, 57, 59, 61, 64, 67, 68, 74-79, 94, 100, 104, 145, 148, 164, 166-170 SPIONs are applied 
as molecular imaging probes due to their monodisperse size distribution, but for biomedical 
applications, a surface modification [i.e., with poly(2-hydroxyethyl aspartamide)] is necessary 
to make them stable under physiological conditions and to avoid the uptake by phagocytic 
cells.57 A recent publication has shown their use for gene therapy. Lin et al.74 discovered that 
SPIONs conjugated with small interfering RNA (siRNA) were able to silence the target 
messenger RNA, consequently reducing the expression of P-glycoprotein (P-gp), a cell 
membrane protein responsible for multidrug resistance. Through this gene therapy, the authors 
demonstrated an excellent down-regulation of P-gp in MCF-7/ADR human BC cell lines in 
orthotopic mouse model. 
In the same way as that of SPIONs, other small size (5-8 nm) magnetic nanoparticles (MNPs) 
have also shown the same characteristics in terms of biodistribution, and the ability to carry 
more compounds thanks to their high surface availability.58, 69, 70, 72, 73, 83, 102, 125, 126, 131, 134, 139, 153, 
171 In this context, Yigit et al.171 used MNPs linked to microRNA (miRNA) for gene therapy. 
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The treatment of human BC cells (MDA-MB-231) in vitro and in vivo with the nanocomplex 
down-regulated a pro-metastatic microRNA (miR-10b) arresting the metastatic process, and 
thus preventing the formation of lymph node metastases. Regarding QDs, it was found that they 
are in the third position as nanomaterials for imaging. Thanks to their fluorescence properties 
upon excitation, their high brightness and photostability, they represent unique nanomaterials 
ideal for in vivo imaging in animal cancer models, as shown in the measurement of the receptor 
expression level of type I insulin-like growth factor receptor (IGFIR) involved in BC 
proliferation and metastasis.122 QDs have been coated with polymer to enhance 
biocompatibility,64, 89, 92, 95, 101, 114, 120, 133, 172 or conjugated with antibodies to detect 
overexpressed receptors.85, 88, 90, 91, 98, 99, 107-110, 116, 122, 135 
The fourth position is held by gold nanoparticles, used for tumor detection, diagnosis, and 
cancer therapy, due to the possibility of an easy surface modification.173 The advantages of 
these nanomaterials include non-cytotoxicity, chemical stability, and high affinities for 
biomolecules.121 Indeed, they can scatter visible and near-infrared light through surface 
plasmon resonance, and thus they have been used in many microscopic techniques including 
CLSM,121, 130, 174 CT,113, 147, 149, 150, 152 FI,5, 87, 103, 113 and other imaging techniques like X-ray,150, 
152, 160 NIR imaging141 and SERS.155, 175 Finally, other imaging nanomaterials (Figure 5B) such 
as poly(lactic-co-glycolic) acid nanoparticles (PLGA),71, 80, 97, 176 mesoporous silica 
nanoparticles (MSNs),75, 86, 140, 142 liposomes,93, 100, 144, 146, 177, 178 silica- AuNSs,56, 137, 154, 165 gold 
nanorods (GNRs),78, 84 carbon nanotubes (CNTs),82, 129 nanoglobules 62, 66, graphene oxide,115, 
163 and nanodiamonds (NDs)179 have been studied for breast tissue imaging and cancer therapy. 
3.5 Theranostics 
Recently, nanotechnology has provided new strategies that combine therapy and diagnosis 
approaches. The introduction of the word “theranostics” represents a well-established field of 
nanotechnology where multifunctional materials can be used for the detection and treatment of 
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cancer disease in a single procedure. Of particular importance is the simultaneous combination 
of contrast agents and therapeutic functions using chemically-modified nanoparticles or 
fluorescent probes.180, 181 A characterisation of all theranostic applications was found in the 
literature for BC. Regarding nanoparticles, MNPs are in the first position in terms of theranostic 
materials investigated, followed by calcium phosphosilicate composite nanoparticles 
(CPSNPs), liposomes, AuNPs and GNRs, AuNSs, CNTs and polymers (Figure 6).  
 
Figure 6. List and acronyms of nanomaterials used as theranostic in the treatment of BC 
 
Theranostic MNPs have demonstrated excellent performances in tumor detection,182-185 drug 
delivery,184, 185 and cancer therapy in mice model studies.186, 187 Part of the works examined 
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as preliminary studies to evaluate the response to cancer therapy. Basuki et al.188 described the 
theranostic application of MNPs loaded with polymers and Dox in in vitro experiments using 
MCF-7 on H1299 human cell lines. The authors demonstrated the accumulation of MNP-Dox 
in lungs and BC cell lines through MRI and Dox release to cancer cells using CLSM and FI 
techniques. For theranostics, GNPs, AuNSs have raised interest in photodynamic therapy,190, 
191 photothermal therapy,180, 192-194 ultrasonography192 and gene therapy.180  
On the other hand, in the context of imaging, AuNPs have shown the main applications 
regarding tumor detection.18, 29, 195-200 
In the third position other known theranostic materials can be found, such as MSNs used for 
tumor targeting and drug delivery,30, 201-203 GNRs for tumor detection and drug delivery,31, 32, 
204 gene therapy,205 and photothermal therapy.206, 207 Liposomes have been used for tumor 
detection and drug delivery,46, 50, 208, 209 and other new theranostics systems like CNTs48, 210-213 
and CPSNPs.214, 215 In particular, CNTs have good echogenic properties like contrast agents, 
with a promising future in the field of theranostic applications.216 Even though positioned in 
the fourth position, QDs have acquired more importance in the field of theranostic applications. 
Rizvi et al.217 reported an in vitro experiment using QDs loaded with antibodies for HER-2 
localization in fixed and live cells (SK-BR-3 and MCF-7 cells). This study underlines how QDs 
coated with mercaptoundecanoic acid appeared to be non-toxic up to 24 h of exposure, and an 
excellent in vitro imaging agent. For this reason, QDs can be potentially used for targeted 
therapy in image-guided surgery and cancer therapy to directly destroy tumor cells. In addition 
to traditional nanomaterials, the combination of polymeric materials has opened a new way for 
theranostic nanomaterials, known as nano-complexes (Figure 6). Their properties have allowed 
a controlled release of drugs in addition to many medical applications, like photoacoustic 
tomography,218 photothermal therapy,219-221 photodynamic therapy,222 drug delivery37, 49, 223-229 
and cancer therapy.230-234 
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During the last years, graphene-based materials have been investigated in biomedical 
applications thanks to its unique intrinsic chemical and physical properties.235 Excellent 
electrical conductivity, ideal photothermal response, large surface area, and versatile chemistry 
have stimulated researchers to explore graphene based materials for applications in tissue 
engineering, drug delivery, molecular imaging and others. For example, Shi et al.236 reported 
reduced GO (rGO) as an excellent photothermal agent that enabled in vivo tumor ablation. rGO 
could be also used as theranostic materials to integrate imaging and therapeutic components to 
fight cancer.236 Recent studies of nanotechnology based on other carbon nanomaterials such as 
NDs, CNTs, and fullerenes have provided good results about their possibility to become 
theranostic agents in the different field of nanomedicine such as drug delivery, regenerative 
medicine, bioimaging. Carbon nano-onions (CNOs) showed the same vectorization 
characteristics possessed by CNTs, as described in a previous work.237 Recently Bartelmess et 
al.238 demonstrated the simple cell-penetration capability of CNOs in an in vitro MCF-7 human 
BC cell line. Boron dipyrromethene (BODIPY) functionalized CNOs exhibited high 
fluorescence intensity for high-resolution imaging and did not show significant toxicity effects. 
These results prove that modified CNOs can be used as new theranostic materials that are able 
to combine imaging, targeting and therapeutic modalities. 
3.6 Conclusions 
A thorough and detailed review of nanoscale innovations against BC proposed in the last nine 
years has been carried out, evidencing increasing interest in the study of nanotechnological 
applications to BC. Nanotechnology offers a possibility for early breast lesion detection and 
searching for more efficient therapies to significantly impact the degree of mortality of BC 
patients. Despite numerous studies on the application of nanotechnology in medicine, the 
hypothetical benefits still need to be clarified. Most of the nanomaterials tested have not been 
able to provide high efficiency for clinical use. Considering the intrinsic physicochemical 
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properties of nanomaterials and all studies analyzed here, superparamagnetic iron oxide 
nanoparticles, quantum dots and liposomes represent the best choice as advanced drug carriers 
for BC therapy. On the other hand, gold silica nanoparticles, nanoshells, nanorods, nanocages, 
and nanotubes were especially studied as photothermal agents under radiofrequency or 
magnetic field activation in non-invasive imaging and cancer therapy.239 Regarding drug 
delivery, nanoparticles have been engineered as drug vehicles to bring the drug directly to the 
tumor site, to reduce toxic side effects of antineoplastic agents, and to enhance combinatorial 
drug delivery. Among all the reported studies, the most promising ones have been highlighted. 
Recent studies have focused on new strategies based on a combination therapy through a co-
administration of multiple drugs using a single treatment. For example, this approach was 
carried out by Murugan et al.240 to describe nanocarrier mediated inhibitory effects of topotecan 
and quercetin on BC cells like a new targeted therapeutic strategy to treat cancer. These 
revolutionary nanocarries have shown an excellent intracellular release of loaded drugs with 
important molecular-induced modifications leading to structural changes in the endoplasmic 
reticulum, nucleus and mitochondria of tumor cells.240 
Nanotechnology can offer potential nanomaterials for creating new methods for detecting, 
targeting and killing BC cells at different stages. Several authors reported the problematic use 
of many nanomaterials because of their non-specific toxic effects in in vivo animal models. One 
of the major advantages of using nanoparticles is based on the possibility to modify their 
characteristics to face physical and biological barriers after injection. However, the analysis of 
the recent publications disclosed that the delivery efficiency has not improved during the last 
nine years.  
Regarding innovative approaches that are able to accelerate nanotool integration into the clinic, 
it is important to mention single cell techniques and in particular single cell mass cytometry. 
Being aware that single cell mass cytometry can be useful in the context of BC as proven 
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recently by the group of Bodenmiller,241 the interest in the application of this approach on 
nanotools to validate their effect on BC treatment becomes clear. 
In conclusion, despite the numerous studies found in the literature, only a few nanomaterials or 
nano-compounds will move on from the pre-clinical phase and will be selected for clinical 
trials. Indeed, the research on biocompatibility is still at an early stage. At present, the 
possibility to control the transport of nanoparticles transport and the real delivery efficiency in 
the body for cancer treatment remains the real challenge for nanotechnology-based tools against 
BC. 
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Chapter 4. Nanotechnology and bone loss dysfunction 
under microgravity condition 
4.1 Introduction 
Bone loss is one of the main problems associated to long spaceflight missions, quantified as 
total bone mineral density (BMD).1, 2 Several experiments of Russian MIR, American and 
European missions conducted by astronauts or simulation models have described the variation 
of both pre-flight and post flight bone loss.3-6 During the missions on the International Space 
Station (ISS) it was found that such loss is usually in the range between 3.0 and 10.0%. 7, 8 
Many authors have described the negative effect of microgravity that acts by altering the bone 
structure of ex-vivo models.9-11 Indeed, it is well known that microgravity (MG) is able to induce 
bone loss in terms of a mineral density decrease of about 2% in 30 days, while a similar decrease 
occurs in women affected by osteoporosis in about 1 year.12 Many researchers described that 
the primary symptoms appearing while in orbit are loss of calcium within the first 10 days after 
the beginning of the space flight and bone changes within 20 days during short missions 13, 14. 
Many of the experiments evaluating the effect of microgravity on cells were studied using short-
duration microgravity simulation.15-18 Moreover, many studies are now assessing the effects of 
microgravity on cells and physiology under long-duration MG simulation experiment.19-23 
Recently, Tavella et al., investigated the alterations of bone microarchitecture using animal 
models during 91 days on the ISS. The authors described that microgravity is able to induce 
bone loss due to a decrease of bone deposition and an increase of bone resorption in wild type 
(Wt) and pleiotrophin-transgenic (PTN-Tg) mice.24 Numerous study have demonstrated that 
short and long spaceflight cause the dysregulation of stem cells functions which leads to the 
inability of cells to repair and regenerate lesions.25, 26 These findings indicate that microgravity 
leads to several modifications in osteoblasts and osteoclasts in terms of cellular morphology, 
proliferation and differentiation.27-29 Experiments carried out on osteoblastic cell cultures, using 
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a tridimensional clinostat as the Random Positioning Machine (RPM) to simulate microgravity, 
are focused on the investigation of spaceflight-related osteoblastic dysregulation.30, 31 Recently, 
Wengui et al. reported in an innovative study that primary cilia (key sensor and functioning 
organelles) of rat calvarian osteoblasts (ROBs) vanished after microgravity exposure.32 In 
addition, the authors underlined that the differentiation and mineralization of ROBs were 
associated with the abrogation of primary cilia after simulated microgravity. Reconstruction of 
primary cilia may become a potential therapeutic approach against bone loss during space 
missions but also in human disease-related bone loss. To address the problem of the 
modification of osteoblasts and osteoclasts in microgravity, several groups have used different 
approaches, such as the use of RPM or Rotary wall vessel bioreactors (RWV) to simulate 
microgravity conditions33, 34. Furthermore, many authors have established that experiments 
conducted using RPM to simulate microgravity have clarified the gene expression 
dysregulation of important osteogenic-related osteoblastic genes, such as osteocalcin (BGLAP) 
and alkaline phosphatase (ALP).31, 35 Nevertheless, the mechanisms of microgravity action on 
osteogenesis inhibition are actually unclear and need to be clarified. A recent review pointed 
out the attention of the current knowledge on the use of stem cells and specialized cells under 
simulated microgravity (RWV and RPM) for tissue engineering applications.36 Many studies 
on the effects of microgravity on bones are carried out using human bone marrow-derived 
mesenchymal stem cells (hBM-MSCs) cultures, which are multipotent cells present in the bone 
marrow.37 Their potential to differentiate into osteoblastic lineage and their applications in the 
studies of bone regeneration are also well known.38, 39 As already reported, MHA/Coll 
particularly enhanced the early expression of crucial osteogenesis associated genes, such as 
ALP and BGLAP in vitro, and the early formation of de novo bone mass in an ectopic model 
in rabbit. 40 Under this perspective, the osteoinductive potential of 3D scaffold to induce human 
bone marrow-derived mesenchymal stem cells (hBM-MSCs) differentiation under long-
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duration microgravity condition was evaluated. Indeed, it was previously demonstrated that 
MHA/Coll thanks to its particular nanostructure and biomimicry could induce the expression 
of osteogenesis associated marker genes in the hBM-MSCs.40 Following this line of research, 
the present work aims to investigate the osteoinductive potential of MHA/Coll in counteracting 
microgravity dysregulation. The viability and differentiation of hBM-MSCs cultured on 
scaffold were determined following the exposure to the osteo-differentiation inducing media. 
Furthermore, the expression of osteoblastogenesis-associated genes was analysed in 
comparison to un-induced controls under MG.  
4.2 Materials and methods 
Scaffold fabrication and structural characterization  
The biomineralization of MHA/Coll scaffolds have showed mineralized nanofibers (89 ± 1,2 
nm) as described elsewhere (Minardi et al, 2015).40  The group of Minardi et al, have used 
nanomaterials during the synthesis phase of MHA/Coll.40  Thanks to the nanomineralization, 
the 3D scaffold is considered a nanomaterial because of the presence of nano porosity due to 
the nanostructured fibers as already described (Minardi et al, 2015).40 
Briefly, an acidic solution of bovine type I collagen (Nitta Casing Inc.) was prepared at a 
concentration of 10 mg/mL in acetate buffer at pH 3.5. H3PO4 was added to 100 g of the acetic 
collagen solution (40 mM), and dropped in a solution of Ca(OH)2 (40 mM) and MgCl2·6H2O 
(2 mM) in DI water. The material was crosslinking in an aqueous solution of 1,4-butanediol 
diglycidyl ether (BDDGE) (2.5 mM). The resulting slurry was molded in 48-well plates at a 
thickness of 3 mm. Finally, the slurry was lyophilized through an optimized protocol, to 
generate the desired porosity and pore size. Non-mineralized collagen scaffolds (Coll) were 
also synthesized, and used as controls 40, 41. All chemicals were purchased from Sigma Aldrich. 
The scaffold was imaged by scanning electron microscopy (FEI Quanta 400 SEM). The 
scaffolds were sputter coated with 10 nm of Pt/Pd, via a Plasma Sciences CrC-150 Sputtering 
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System (Torr International, Inc), and imaged at a voltage of 7.5 kV. Fourier-transformed 
Infrared spectroscopy (FTIR) was performed through a Nicolet 4700 Spectrometer. 64 runs 
were performed per sample. Spectra were analyzed by the software EZ OMNIC (Nicolet). The 
amount and thermal properties of mineral phase nucleated on the organic template (type I 
collagen) was assessed by thermal gravimetric analysis - differential scanning calorimetric 
(TGA-DSC). The samples (n=3) were placed in alumina pans and subjected to a heating ramp 
from 25 ºC to 800 ºC, at 10 ºC/min. A Q-600 TGA was used (TA Instruments). 
MHA/Coll characterization under MG 
MHA/Coll structure and hBM-MSCs morphology after long duration microgravity exposure 
was observed using scanning electron microscopy (SEM). For SEM morphologic investigation, 
the samples were fixed in 2.5% glutaraldehyde in 0.1 M phosphate-buffer (pH 7.2) and post-
fixed in 1% Osmium Tetroxide (OsO4), dehydrated in a graded acetone series and dried by 
critical point method in an Polaron Jumbo apparatus (Polaron Equipment, Watford, UK) coated 
with gold in an Edwards S150A Sputter Coater unit (Edwards, Crawley, UK). The specimens 
were examined with a Zeiss DSM 962 scanning electron microscopy (Zeiss, Oberkochen, 
Germany). 
Stem cell culture in 2D condition 
Human Bone Marrow-Derived Mesenchymal Stem Cells (hBM-MSCs) (ATCC®PCS-500-
012™) were cultured in α-minimum essential medium (α-MEM), containing 10% of heat-
inactivated fetal bovine serum (FBS), 2% of glutamine, and 1% of human Fibroblast Growth 
Factor-Basic human (bFGF) (all from Gibco). Adherent cells were passaged at 80% confluency 
using TripLETM Express (Invitrogen) and reseeded for culture expansion.  
Microgravity simulation 
Microgravity was simulated by a random position machine (RPM). The RPM from Fokker, 
Netherlands is a tridimensional clinostat able to produce a multilateral gravitational simulation 
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when the samples are set in the center of the machine. A computerized program was used to 
create random movements and slow rotation of the two axes of the RPM in order to provide 
microgravity simulation (M; 0 x g). Static controls and the same samples were placed in the 
basement of the RPM to simulate the gravity condition (G; 1 x g).  
hBM-MSCs viability assay  
Cell viability was evaluated by Flow cytometry (FACS Canto II, BD Biosciences, Mountain 
View, CA, USA) using 7-AAD (7-amino-actinomycin D) staining (BD Bioscience, San Josè, 
CA, USA). hBM-MSCs cells were seeded into scaffolds as previously described and evaluated 
after 7, 14 and 21 days under microgravity conditions. To collect cell, the scaffold was washed 
three times in PBS and then digested using 2 mg/ml Collagenase I (Life Technologies) diluted 
in media without FBS. The cell pellet was washed in PBS to eliminate collagenase and 
afterwards cells were stained with 7-AAD, incubated for 20 min in the dark and suspended in 
PBS 1x solution for the flow cytometry analysis.  
Induction of hBM-MSCs differentiation on MG conditions  
Undifferentiated hBM-MSCs were harvested and prepared for 3D culture. A 30 µl drop 
containing 350,000 cells was seeded in the center of MHA/Coll scaffold and kept in incubator 
for 10 min. In order to evaluate the osteogenic potential of MHA/Coll, differential medium 
(StemPro® Osteogenesis Differentiation Kit, Gibco) supplemented with 25 mM of 1M HEPES 
buffer solution (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, Gibco), as an organic 
chemical buffering agent, was added to each MHA/Coll and positive control. RPM-cultures 
were mounted horizontally in the center of the RPM at 37 °C. Identically the same number of 
cultures was placed in the same room of RPM at 37 °C in horizontal position to provide a 
control of samples grown under gravity condition (1 x g). Mesenchymal stem media was used 
as the negative control.  
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Gene expression analysis  
Total RNA was isolated from cells using TriZol Reagent (TriZol, Invitrogen, Carlsbad, CA, 
USA). RNA purity and concentration were measured with Nanodrop Spectrometer 
(Nanodrop® ND1000). cDNA synthesis was performed using Superscript IV Reverse 
Trascriptase kit following the manufacturer protocol (Life Technologies). Amplification was 
performed using TaqMAN probes and TaqMan® Fast Advanced Master Mix (Applied 
Biosystems). The expression of alkaline phosphatase (ALP, Hs01029144_m1) and osteocalcin 
(BGLAP; Hs01587814_g1) was evaluated. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH; Hs02758991_g1) was used to normalize gene expression results respect to ctrl-MSC. 
The gene expression analysis of the osteogenic genes was performed comparing hBM-MSC 
cultured on MHA/Coll and hBM-MSC cells cultured with osteogenic media (induced MSC), 
or non-induced (Ctrl-MSC) under gravity and microgravity conditions. Polymerase Chain 
Reaction (PCR) was performed on plates using a CFX96 Real Time instrument (Bio-Rad). 
Statistical analysis 
Data analyses were performed using Prism GraphPad software. Statistics for experiments was 
performed using a One-Way ANOVA. In all cases * was used for p < 0.05, ** for p < 0.01, and 
*** for p < 0.001, and **** for p < 0.0001. Values were expressed as mean ± SD. Flow 
cytometry data were analyzed with FACS Diva software (BD-Bioscience Mountain View, CA, 
USA). Osteo-gene expression data were calculated by the comparative threshold cycle method. 
All experiments were performed at least in triplicate. 
4.3 Results and discussion  
Characterization of MHA/Coll 
The architecture and structure of Coll and MHA/Coll were evaluated by SEM (Figure 1). The 
lower magnification images revealed the high porosity and regular pore size of Coll (Figure 
1A), while it showed the anisotropic nature of MHA/Coll (Figure 1B). The higher 
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magnification micrograph of MHA/Coll confirmed the full mineralization of the collagen fibers 
with an amorphous apatite phase, accomplished during the bio-inspired process of synthesis 
(Figure 1C). The chemical interaction between the mineral phase and the type I collagen fibers 
of MHA/Coll was confirmed by FTIR spectroscopy (Figure 1D), where a shift from 1340 to 
1337 cm-1 in the band corresponding to the stretching of -COO- group of collagen was observed. 
The TGA-DSC analysis, displayed that the overall mineral phase content in MHA/Coll was 
approximately 56 wt% (Figure 1E). Finally, MHA/Coll structure were evaluated by SEM on 
gravity condition (Figure 1F) and microgravity exposure (Figure 1G), showing the 
remodelling action played by microgravity long exposure. 
 
 
Figure 1. Scaffold architectures. Scaffold structure characterization by SEM of Coll (A) and MHA/Coll (B). The 
higher magnification micrograph of MHA/Coll (C) shows the collagen fibers with a full mineralization and an 
amorphous apatite phase. D) FTIR spectra showing the chemical interaction between the mineral phase and the 
type I collagen fibers of MHA/Coll. E) Evaluation of the mineral phase on MHA/Coll by TGA-DSC analysis. F) 
SEM micrographs of MHA/Coll structure after 21 days of exposure (G, 100x). G) Disfiguring action of 
microgravity on MHA/Coll structure (MG, 100x). 
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MG effect on MHA/Coll structure and hBM-MSCs morphology  
It was previously found that MHA/Coll was able to mimic the osteogenic niche of human 
trabecular bone.40 MHA/Coll is synthesized through a sophisticated bio-inspired 
nanotechnological process, which recapitulates the chemical, physical, morphological and 
structural control mechanisms of the natural biomineralization process.42 During the synthesis, 
a partial substitution of the calcium with magnesium ions in the apatite lattice allows for an 
amorphous nanostructured apatite, which more closely mimics that found in the early 
osteogenic niche.43 Following the current findings, the microgravity effects on MHA/Coll 
structure were evaluated by SEM (Figure 2). 
 
Figure 2. Evaluation of MG effect on cells morphology. SEM micrographs of MHA/Coll at 1000x on gravity 
(A) and disfigured structure of MHA/Coll after microgravity conditions (D). B) Induced- hBM-MSCs attachment 
onto the fiber of the scaffolds after 21 days seeding taken on the center of the scaffold surface on gravity condition. 
C) Particular of Induced- hBM-MSCs at 2000x. E) Induced- hBM-MSCs on simulated microgravity condition. F) 
Particular of induced- hBM-MSCs at 2000x. White arrows indicate the change on cell morphology under 
microgravity. 
 
MHA/Coll on gravity condition (Figure 2A) revealed a fibrous structure and a correct 
alignment of the fiber which forming the niche. On the contrary, MHA/Coll on microgravity 
long exposure (Figure 2D), displayed a disfiguring effect by MG on the fiber, providing a 
different structure of the niche. Figure 2B shows the induced- hBM-MSCs morphology after 
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21 days seeding taken on the center of the scaffold surface on gravity condition. At higher 
magnification, induced- hBM-MSCs appeared alive and in connection together attached onto 
the Nano mineralized fiber of the scaffolds. Morphology changes induce by long exposure of 
simulated microgravity are showed in Figure 2E. The induced- hBM-MSCs appeared in an 
altered morphology resulting to be flattened respect to the condition in gravity (white arrows, 
Figure 2E and Figure 2F). This effect is due to the remodelling action of the microgravity, 
which causes the partial destruction of the scaffold fibers and consequently the altered cellular 
morphology. Figure 2F shows the flattened cells on the linear surface of the scaffold. When 
three-dimensional niches are missing, the cells are not able to adhere to the fibers and appear  
to be flattened respect to the gravity condition (Figure 2C). A recent publication described that 
mesenchymal stem cells under RPM simulation respond to microgravity exposure inducing the 
upregulation of some osteogenic transcripts due to activate the differentiation process.44 In 
detail, only the addition of particular osteogenic cocktail can complete the full cellular 
differentiation process both in gravity and microgravity conditions.44 In accordance with this 
study, the microgravity simulation alone can act the hBM-MSCs differentiation toward a 
complete osteogenic phenotype only after a specific stimulus exposure.  
According to these studies, observing the data collected in this work, it is possible to 
hypothesize that the altered morphology of differentiated cells showed in MG is due to the 
disfiguring action of microgravity on nanostructured fibers with remodelling effect on the 3D 
niche. These results supported such hypothesis and clearly underlined that the mineralization 
in the nanoscale of MHA/Coll structure (3D culture) is able to induce hBM-MSCs to 
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hBM-MSCs viability assay on MHA/Coll  
Viability analyses of hBM-MSCs were performed using 7-amino-actinomycin D (7-AAD) 
staining, a fluorescent chemical compound with strong affinity for DNA. Cell fluorescence was 
measured by flow cytometry (Figure 3). When excited by 488 nm laser light, 7-AAD 
fluorescence is detected in the far red range of the spectrum (650 nm long-pass filter). Late 
apoptotic and necrotic cells with compromised membranes allow the passage of this dye into 
the nucleus. Flow cytometry data did not exhibit damage in cell viability (Figure 3). Cells on 
MHA/Coll remained alive up to 21 days after MG stimulation. A non-significant difference 
between MHA/Coll in comparison to the control after 7, 14 and 21 days was found (Figure 3). 
 
 
Figure 3. Viability assay of hBM-MSCs cultured on MHA/Coll scaffolds. Human BM-MSCs were cultured on 
MHA/Coll scaffolds (red) in gravity (G) and microgravity (MG) conditions. To assess the viability, the cells were 
stained with 7AAD marker. The histograms report the percentage of 7AAD positive cells (7AAD+) after 7, 14 
and 21 days incubation compared to the un-induced-MSC (black). The experiments were performed at least in 
triplicate with flow cytometry. 
 
Markers of differentiation hBM-MSCs under microgravity 
To investigate the influence of microgravity simulation on the differentiation of hBM-MSCs, 
the expression surface CD- markers was determined in both induced 3D cultures and un-
induced controls. Firstly, CD29 (a β1 integrin associated with late antigen receptors) and CD44 
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(a hyaluronic acid/fibronectin receptor involved in hematopoietic stem cell adhesion, 
mobilization and proliferation), were evaluated for mesenchymal stem cells surface markers 
expression by flow cytometry. The differentiation marker levels under gravity condition and 
microgravity simulation of hBM-MSCs and MHA/Coll cultures were determined after 7, 14 
and 21 days. Figure 4A shows a significant decrease of surface markers expression of 
mesenchymal stem cells, CD29 and CD44, on MHA/Coll in both gravity and MG condition in 
comparison to the un-induced control (P value < 0.0001). It is well known that hBM-MSCs 
showed the capacity to differentiate along osteogenic lineage 45 and the consequent reduction 
in the expression of most surface markers is related to MSCs differentiation.46 Surprisingly, a 
low expression of mesenchymal stem cells surface of these markers under MG was found, that 
showed the possible differentiation of hBM-MSCs on MHA/Coll-G and MG compared to the 
induced-MSC. In contrast, un-induced MSCs and induced MSCs showed no CD29 and CD44 
expression when MG simulation was applied (Figure 4A). The loss of the hBM-MSc surface 
marker was explored in the MHA/Coll differentiation plot using flow cytometry (Figure 4B). 
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Figure 4. MHA/Coll induced hBM-MSCs differentiation under MG conditions. Human BM-MSCs osteo-
differentiation was investigated in MHA/Coll scaffolds under G and MG conditions. A) CD29 and CD44 were used as 
differentiation markers. Un-induced-MSC were used as negative control (black) and induced-MSC were used as positive 
controls (grey) for induced hBM-MSCs on scaffolds. B) Differentiation plot were displayed the hBM-MSCs wich are 
negative for CD45 marker and the differentiated cells, which showed the loss of CD29 marker. The osteogenic 
differentiation assay was assessed in triplicate by flow cytometry on G and MG simulation (***P < 0.001 or ****P < 
0.0001 vs Ctrl of G group; ###P < 0.001 or ####P < 0.0001 vs Ctrl of MG group). C) The differentiation assay was assessed 
looking at the expression of CD90 as a differentiation marker towards osteogenic lineage. A significant difference 
compared to the uninduced-MSC control was observed (**P < 0.01, ***P < 0.001, ****P < 0.0001 ) vs Ctrl of G group; 
##P < 0.01, ###P < 0.001 or ####P < 0.0001 vs Ctrl of MG group). 
 
It is known that hBM-MSc are suggested to be negative of CD45 and positive to CD29 surface 
markers. This is the criterion used to analyze the hBM-MSCs differentiation after 21 days. 
Figure 4B shows the group of CD45-/CD29+ hBM-MSCs in both G and MG condition 
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compared to the controls. More in details, MHA/Coll showed high level of differentiation status 
(red; plot 5 and 6 in G and MG respectively) even after microgravity stimulation in comparison 
to induced MSC-G (gray, plot 3) as negative CD29 cells (Figure 4B). On the contrary, induced 
MSC-MG (gray; plot 4) suggested the dysregulation on the MSC differentiation potential. 
Similarly, un-induced MSC-MG (black; plot 2) displayed no differentiated level equally to the 
un-induced MSC-G control (black; plot 1) as positive CD29 cells. 
Furthermore, to evaluate the osteogenic potential of MHA/Coll under microgravity (M, 0 x g), 
the expression of CD90 (thymocyte differentiation antigen-1, Thy-1), a well-known 
differentiation marker toward osteogenic lineage, was measured. Indeed, it has been reported 
that the expression of CD90 decreases while there is a cell differentiation towards osteoblast-
like cells.47 CD90 was assessed on MHA/Coll incubated with induced media under G and MG 
simulation. Induced-MSC and un-induced Ctrl-MSC were used as a positive and negative 
control, respectively. Induced MSC-G suggested a significant decrease level of CD90 
expression (P value < 0.001) in comparison with the induced MSC-MG, which confirmed the 
dysregulation on the osteogenic differentiation due to microgravity exposure (Figure 4C). 
Intriguingly, the CD90 marker suppression of MHA/Coll was more significant compared to the 
induced MSC-G (P value 0.001) after 21 days in both conditions (G, P Value 0.0001 and MG, 
P value 0.0001), evidencing the passage towards the osteogenic lineage compared to the 
undifferentiated control (Figure 4C). The decrease of CD90 level of induced MSC-G was 
observed between 14 and 21 days (P value < 0.001), which demonstrates the hBM-MSCs 
differentiation during induced media exposure.  
The results here discussed demonstrated that the low expression of CD29, CD44 and CD90 
level on both MHA/Coll G and MG, indicating that the structure of the scaffold with 
nanostructured niche may help the differentiation into osteogenic cells under microgravity 
simulation.  
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hBM-MSCs osteogenic differentiation on MHA/Coll under MG 
To investigate the osteogenic differentiation under microgravity, it was decided to assess the 
next gene expression experiment using the time point of 21 days on MHA/Coll. Firstly, the 
molecular changes of induced hBM-MSc were investigated, performing a genomic analysis on 
the expression of two highly representative osteo-differentiation genes. The purpose was to 
evaluate the expression of osteoblastic genes onto MHA/Coll scaffolds under microgravity 
simulation (Figure 5).  
 
 
Figure 5. Osteogenic differentiation on MHA/Coll after MG. The main genes involved in osteoblast 
differentiation were analyzed using Real-Time PCR: alkaline phosphatase (ALP) and osteocalcin (BGLAP). 
Statistical significance (ANOVA test) is indicated by *** = p < 0.001 or ** p = < 0.01 for G group vs Ctrl G; by 
### = p < 0.001 or ## = p < 0.01 for MG group vs Ctrl MG. Bars indicate the compared samples under different 
conditions. 
 
The gene expression analysis on MHA/Coll MG, showed an increase expression level of ALP 
(P value < 0.01) and BGLAP genes (P value < 0.01) compared to the un-induced MSC-MG 
(ctrl) and a significant difference between MHA/Coll MG vs induced MSC-MG (P value < 
0.01). On the contrary, induced MSC-MG showed the lower expression gene levels under 
microgravity condition, underlining the dysregulation effect played by microgravity. The 
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osteogenic gene expression profiling played in MG suggested that MHA/Coll can influence 
hBM-MSCs at the molecular level also in microgravity. Together with current findings, this 
suggests that MHA/Coll is able to transfer key cues at the nanoscale to h-MSC, which overally 
results in an increased osteo-differentiation in microgravity conditions. Unlike MHA/Coll, it 
was found that microgravity is able to cause a dysregulation of induced- hBM-MSCs with a 
downregulation of osteogenic markers and genes. These findings are consistent with many 
other studies conducted on microgravity. In fact, many authors described that MG causes a 
dysregulation of osteoblast and osteoclasts with a consequent decrease of bone growth and 
mineralization.48-50 MHA/Coll instead, showed its osteoinductive properties on induced-MSCs 
on gravity and under microgravity stimulations. These results are further confirmed by the 
MHA/Coll osteogenic properties under microgravity which displayed the expression of ALP 
and BGLAP, a group of growth factors associated with the development of bone mineralization. 
4.4 Conclusions 
In this work, an integrative study evaluating the osteoinductive potential of MHA/Coll scaffold 
to promote osteogenic differentiation under long-duration microgravity simulation was 
proposed. The osteogenic differentiation of induced hBM-MSCs cultured into nanocrystalline 
magnesium-doped hydroxyapatite/type I collagen composite scaffold (MHA/Coll) was 
investigated under microgravity simulation. The osteogenic potential of MHA/Coll was 
evaluated using the Random Positioning Machine to simulate microgravity (M, 0 x g). Data 
showed that MHA/Coll with its particular nanostructured niche was able to induce osteogenic 
differentiation of hBM-MSCs even under microgravity simulation, despite the remodeling 
effect played by MG. These results contribute to the understanding of the osteogenic 
capabilities of nanostructured scaffold under long duration microgravity simulation and may 
help counteracting the bone loss dysfunction after prolonged space flights and weightlessness 
but also bring new knowledge for the development of scaffolds and materials able to counteract 
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human bone loss disease. Despite the MG negative effect on the structure of scaffold, the 
collected data emphasize the importance of osteogenic capabilities of nanostructured 
MHA/Coll such as future excellent candidates for bone regeneration in microgravity studies. 
Furthermore, this study provides a significant contribution to evaluate new nano-materials for 
regenerative medicine and tissue engineering for use in spaceflight mission and Earth-based 
disease research. 
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Chapter 5. Nanotechnology and malaria 
5.1 Introduction 
Malaria represents one of the most common infectious diseases, which has become one of the 
most impellent public health problem worldwide.1 Malaria disease is due to the mosquito bite 
that is able to infect humans introducing different species of Plasmodium into the host.1 Among 
various species, P. falciparum represents the most dangerous and lethal parasite that infects 
humans.2 It was estimated that P. falciparum is one of the leading causes of death in the tropical 
and subtropical countries with 429.000 deaths and 212 million new cases in 2016.3 However, 
by considering the current drugs accessible for the prevention and treatment of this disease, it 
seems that, despite the effectiveness of available antimalarial treatments, the main threaten 
connected to malaria is the emergence of drug resistance.4, 5 In this context, nanotechnology 
could represent a possible future solution against malaria by introducing the control of drug 
release at the nanoscale or building active nanoparticles to be used against the parasite. In the 
last decades, the applications of nanotechnology have been mainly focused on the development 
of a large variety of nanoscale tools designed for their use in therapy 6, 7 and malaria can be one 
of their targets. Recent advances in nanotechnology have led to the improvement of drug 
delivery strategies in order to overcame the barriers found in several conventional therapeutic 
drugs.8-11 Among different nanomaterials, metal nanoparticles have been significantly studied 
thanks to their particular physical and chemical properties as an alternative theranostic tool for 
treating human diseases.12-14 In this context, among several noble metals, silver nanoparticles 
(AgNPs) represent an ideal material for biomedical applications, and it has been largely 
investigated during the last years.15-17 Its use became less frequent with the introduction of 
antibiotics in the 1940’s, but it is slowly regaining popularity as antibiotic resistance became a 
serious threat to public health18. In fact, bacterial resistance to silver is very rare, and 
documented in just a few particular cases.18 In the past two decades a huge number of silver 
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compounds, mainly coordination complexes, have been prepared and showed promising 
antibacterial or, more interestingly, anticancer activity, sometimes higher than the reference 
compound for cancer treatment, cisplatin.18 Unfortunately, such activity was evident only in in 
vitro experiments, while the applications in vivo suffered the limits deriving from scarce 
bioavailability of the active species (Ag+) inside the body once the drug was administered to 
animal models.18 Researchers are trying to overcome these problems, and the route leading to 
successful silver-based drugs seems to pass through the preparation of silver nanoparticles.18 
According to the literature, silver nanoparticles are toxic for prokaryotic organisms, but 
relatively safe for eukaryotic species, including humans.18 Their cytoxicity is probably 
associated to several characteristics of the nanoparticles, including reactivity in solution, size 
distribution, shape, coating/capping, all factors depending on the method of synthesis used to 
prepare them.18,19 Indeed, conventional physical and chemical methods for AgNPs synthesis 
employ reagents and solvents that can be toxic, and are rather expensive.20, 21 Thus, the synthesis 
of eco-friendly metal nanoparticles using biological fluids represents a new growing field of 
nanotechnology for nanomedicine applications.22 Generally, plants extracts, plant-based 
phytochemicals, bacteria, algae and other biological sources are used as reducing agents in the 
preparation of nanoparticles. According to the published literature, biologically-synthesized 
AgNPs seem to be relatively soluble, showing high stability and less toxic effects.23-25 Despite 
the synthetic routes and reaction conditions, the advantages of the biosynthesis approach are 
the high efficiency and inexpensiveness of the methods and the production of relatively non-
toxic and safe nanoparticles for translational research.26-28 The biological activity of AgNPs 
depends on different characteristic such as particle reactivity in solution, size distribution, 
coating/capping of the nanoparticles that influence their cytotoxicity.29 As previously 
mentioned, plant extracts are highly effective in reducing silver ions into AgNPs possessing 
biological activity, and among them many species of the genus Artemisia have been 
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investigated for their action against bacterial and cancer cells with promising results.30, 31 This 
effectiveness is undoubtedly linked to factors like size and shape of the AgNPs, but their 
capping is at least as much important. Several studies have reported that biomolecules contained 
in the plant extracts such as phenols, flavonoids, enzymes and other proteins not only lead to 
the reduction of silver ions to form nanosized particles, but also provided a useful capping on 
the nanoparticle surface.32 Such capping is able to influence the particle size and avoid 
aggregation;33 moreover, it allows a better internalization of the AgNPs by the cells and 
determines a lower cytotoxicity.34 A large variety of compounds have been extracted from 
Artemisia annua plants, in particular artemisinin, which is used as an anti-malarial drug.35 
Considering all the advantages of “green” AgNPs and Artemisia properties, the synthesis of 
silver nanoparticles has been carried out using two different types of Artemisia (annua and 
arborescens) extracts, and the AgNPs thus prepared have been assessed for their activity against 
P. falciparum parasite.  
5.2 Materials and methods 
Cell cultures  
The Palo Alto (PA) strain represents a reference parasite strain to study various antimalarial 
drugs in P. falciparum.36 PA strain was isolated from a Ugandan patient and is considered as a 
reference strain due to its high genetic stability. P. falciparum PA strain (mycoplasma-free) 
was cultivated in RPMI 1640 medium containing HEPES (R5886 Sigma Aldrich), 
supplemented with 20 mM glucose, 2 mM glutamine (59202C Sigma Aldrich), 0.025 mM 
adenine, and 32 mg/L gentamycin at 2% hematocrit. Parasite cultures were synchronized as 
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Synthesis of silver and green nanoparticles 
A. annua plants were purchased from an accredited plant grower in Puglia. A. arborescens 
leaves were collected in a growth spot in the countryside around Sassari. Fresh A. annua and 
A. arborescens leaves were collected in the months of February and March.  
Silver nitrate, ethanol and all the chemicals used were purchased from Sigma-Aldrich Europe. 
Silver nanoparticles have been prepared using either a protocol reported in the literature by 
Khatoon et al.33 or a personally modified version of the former. In the first protocol, fresh A. 
annua and A. arborescens leaves (10 g) were extracted in 100 ml of 50% ethanol at 60° C. 
Then, the extracts were filtered, diluted with 50% milliq water and 100 mL of this solution were 
slowly added to 900 ml of aqueous AgNO3 (2 mM) at room temperature to obtain the desired 
nanoparticles within a couple of hours. In the modified protocol, Artemisia leaves were 
extracted at a lower temperature, 50° C, to avoid cleavage of the peroxo bridge in artemisin. 
100 ml of the hydroalchoolic extracts were diluted to 500 mL with milliq water and slowly 
added to 500 mL of 2 mM AgNO3 under magnetic stirring at room temperature. Reaction was 
complete within a couple of hours. To label the A. annua-AgNPs synthesized with the two 
different methods, (1) will be used to indicate the modified protocol and (2) for the first method 
reported in the literature, as previously described. Silver nanoparticles have also been 
synthesized through a classical chemical approach (0.1 M AgNO3, 0.3 mM ascorbic acid as the 
reductant and 0.3 mM sodium citrate as the stabilizer at pH 10.5 (method 3) and 13 (method 4), 
respectively) at 30° C and used as the control.  
Characterization of nanoparticles 
The Transmission Electron Microscopy analysis (TEM) observations were performed on FEI 
TECNAI G2 F20 TWIN instrument using an accelerating voltage of 200 kV. The Energy 
Dispersive X-ray Spectroscopy was used to collect the spectrum of elemental analysis. Samples 
for TEM and EDAX analysis were prepared by dispersing a small amount of nanoparticles in 
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ethanol, sonicated for 20 or 30 min followed by the deposition of one or two drops of the 
suspension on a holey carbon/copper supported grid. The determination of the average size 
distribution of the nanoparticles was performed using the spectroscatterer LB-550, Horiba.  
The dried powder (1 mg) was dispersed in 10 ml of distilled water. The aqueous solution of 
each sample was filtered and then used for dynamic light scattering analysis.  
Evaluation of nanoparticles green capping  
Samples for Fourier Transform Infrared spectroscopy were prepared as KBr pellets using 
nanoparticles (2 mg) and potassium bromide (200 mg) by compressing the dried powders in a 
KBr press. FTIR measurement were performed recording the signals in the 400-4000 cm-1 range 
with a resolution of 4 cm-1. FTIR spectra were recorded using a Vertex 70 Bruker 
spectrophotometer and analysed with OPUS 7 software. UV-visible spectrum of the 
nanoparticles dispersed in acqueus buffer samples was taken to check the absorption bands. 
The spectra were recorded by a Nicolet Evolution 300 UV-vis spectrophotometer. 
In vitro hemo-compatibility assay on parasitized Red Blood Cells 
Fresh human heparinized whole blood was obtained from healthy volunteer donors. RBCs were 
purified from blood by centrifugation at 200 g for 5 min to remove plasma and leukocytes. 
RBCs were then washed three times in sterile complete growth medium as previously 
described. Parasitized RBCs cultures were maintained at 2–5% parasitemia (1% haematocrit) 
at 37˚C in a 95/5% (vol/vol) air/CO2-atmosphere. All assays were performed at this parasitemia 
and hematocrit. Ultrapure water was used as the positive control (Ctrl+). To determine the 
hemolytic activity on pRBCs, nanoparticles suspension (stock = 1 mg/mL) prepared with sterile 
isotonic PBS 1X and 5 mM glucose was added to diluted pRBC culture (0.1 ml, ~ 2 X 108 
cells/mL) at different concentrations (1.25, 2.5, 5 μg/mL) and 24 h times by vortexing. Then, 
samples were centrifuged at 2000 rpm for 1 minute and a microplate reader (Thermo Scientific) 
was used to measure the absorbance of hemoglobin release in the supernatant at 405 nm. 
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Evaluation of growth inhibition of P. falciparum in Palo Alto strain 
Parasite viability and parasitemia of PA strain were determined using Diff-Quick stained thin 
blood smears and light microscopy (Carl Zeiss Standard Microscope Lamphouse 467230). 
Parasitemia was defined as the number of parasites/number of RBCs counted, for a total of 
5000 RBCs. Two thin smears per condition were counted 3 separate times by each of three 
operators. Cultures were synchronized weekly using Percoll separation or 5% sorbitol solution 
treatment37 in order to obtain the first parasite stage (rings) to start the experiments at 0 h. 
Statistical analysis 
Data analyses were performed using Prism GraphPad software. Statistics for experiments were 
performed using a t-test. In all cases * was used for p < 0.05, ** for p < 0.01, and *** for p < 
0.001. Values were expressed as mean ± SD. All experiments were performed at least in 
triplicate. 
5.3 Results and discussion 
Product and purification of “green” nanoparticles 
At a first time, AgNPs have been prepared using Kathoon protocol33 using the leaf extract of 
A. annua plants. Later, a modification of this method was introduced in the attempt to prepare 
particles with smaller size. Figure 1 shows the “green” synthesis process using two different 
types of Artemisia plant (i.e. A. annua and A. arborescens). The choice to use A. annua was 
based on the excellent medicinal properties of its extracts, while A. arborescens was chosen as 
a common species in Sardinia with traditional uses in medicine, and an ancient remedy against 
malaria. In particular, A. annua is an aromatic annual herb that grows endemically in China. 
The major compounds isolated from A. annua have shown different biological activity as 
antimalarial, antibacterial, antitumor and anti-inflammatory agents.38 Among them, 
Artemisinin is a compound with a potent antimalarial effect as it is very active against P. 
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falciparum and other malaria-parasites, its activity being attributed to the alkylation of malaria-
specific proteins.39  
 
The second plant chosen for this study, A. arborescens, grows in ruderal environments on 
calcareous soils in the Mediterranean area40 and is very frequently found on the island of 
Sardinia. Several studies have reported the potential of A. arborescens compounds as 
antibacterial, anti-inflammatory, antioxidant and anticancer agents.40-42 Following these 
studies, an idea emerged as to investigate and to compare the effects of AgNPs grown from A. 





Figure 1. Nanoparticles green synthesis. Schematic representation of “green” AgNPs synthesis using 
A. annua and A. arborescens extracts. 
 
Characterization of nanoparticles  
A critical step in biomedical applications of nanoparticles is to study their chemical composition 
and physical characteristics for a correct characterization in order to correlate the biological 
activity to specific parameters of the nanoparticles (composition, size, shape, capping, etc.). 
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Therefore, to investigate the nanoparticle effects on PA cultures, firstly their chemical structure 
has been studied in order to correlate it to their biocompatibility.  
The biosynthesized silver nanoparticles were characterized using TEM analysis.  
Figure 2A shows the TEM images of AgNPs which were close to spherical shape and not 
homogenous in the size range, lower than 20 nm in diameter. Dynamic light scattering analyses 
were used to evaluate the size distribution of AgNPs in aqueous dispersion. The average size 
of “green” nanoparticles was 13.12 nm for A. annua-AgNPs (1), 11.45nm for A. annua-AgNPs 
(2), and 10.0 nm for A. arborescens-AgNPs (1), respectively (Figure 2B).  
 
 
Figure 2. Green nanoparticles characterization. A) TEM micrographs of A. annua-AgNPs (1) and (2) 
and A. arborescens-AgNPs (1). B) Evaluation of nanoparticles size distribution using dynamic light 
scattering analysis. 
 
All “green” nanoparticles dispersed well in aqueous medium displaying no aggregation in water 
while both silver nanoparticles from the “classical” chemical synthesis appeared to be slightly 
aggregated. EDX profile displayed the elemental composition of the synthetized nanoparticles. 
 Elisabetta Avitabile, Nanotechnology: development of nanotools to counteract human diseases,  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
80 
EDX of “green” AgNPs (Figure 3) shows the silver peak and organic signal due to the capping 
agent/stabilizing agent on the surface of each nanoparticle. The Cu peak is due to the grid.  
 
 
Figure 3. Elemental composition of “green” AgNPs. Evaluation of nanoparticles silver signal using EDX 
profile: A) A. annua-AgNPs (1), B) A. annua-AgNPs (2) and C) A. arborescens-AgNPs (1). Cu and Si peaks 
presented in the graphs are due to the grid used.  
 
Evaluation of “green” nanoparticles surface 
The The evaluation of the structural features of the surface of nanoparticles plays a significant 
role in the understanding of the possible effect of AgNPs on the cell membrane for biological 
applications. FT-IR spectra (Figure 4A) were performed to evaluate the surface composition 
of the “green” nanoparticles compared to “classical” nanoparticles.  
The peak in the range 2800-3200 cm-1 (Figure 4A, panel a,b,c) may be attributed to methanol 
and to phenolic compounds of Artemisia leaf extracts, while it does not appear in “classical” 
AgNPs (Figure 4A; panel d,e). The signals at 1600 and 1000 cm-1 are due to the stretching of 
organic compounds (i.e amide I). On the contrary, the stretching in the range 1400 cm-1 may be 
attributed to silver nanoparticles in accordance with the literature.32, 33 The structural 
characterization of silver nanoparticles synthetized using both Artemisia leaf extract was 
 Elisabetta Avitabile, Nanotechnology: development of nanotools to counteract human diseases,  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
81 
performed using Uv-vis spectroscopy analysis. In Figure 4B, the image of the nanoparticles 
solution color using the different methods of synthesis considered is shown. The initially green 
solution rapidly changed to a brown color when Artemisia extracts were used (Figure 4B; 
panel a, b, c), while it became yellow and then gray during the synthesis of both AgNPs (3) 
and (4) (Figure 4B; panel d,e), respectively. To monitor the synthesis of silver nanoparticles, 
the Uv spectrometer was used.  
The Uv-vis spectra displayed the surface plasmon resonance recorded as a function of the 
nanoparticles methods of synthesis used and their consequent size. Data results indicate that the 
Uv-vis spectra obtained in the range of 400-450 nm wavelength was increased in A. annua-
AgNPs (1) compared to A. annua-AgNPs (2) and A. arborescens-AgNPs (1). Contrariwise, the 
AgNPs (3) and (4) displayed a lower absorbance intensity, due to their high aggregation in 
solution (Figure 4B). Considering the same concentration of nanoparticles used for the 
analysis, the difference in the spectra signal depends on the size, the aggregation and the 
different capping (or absence of capping) of nanoparticles. Indeed, A. annua-AgNPs (1) and (2) 
have demonstrated a lower aggregation in aqueous medium and good shape and dimension 
compared to the other nanoparticles taken into consideration.  
 
Figure 4. Structural characterization of nanoparticles. A) FT-IR spectra of “green” nanoparticles (panel a,b,c) 
and “classic” silver nanoparticles (panel d, e). B) Structural characterization of nanoparticles analyzing the surface 
plasmon resonance by Uv-vis spectra. 
 Elisabetta Avitabile, Nanotechnology: development of nanotools to counteract human diseases,  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
82 
Biocompatibility of “green” nanoparticles 
To study the effect of “green” AgNPs on RBCs biocompatibility, several in vitro experiments 
have been performed on human RBCs infected by P. falciparum. Firstly, PA culture was treated 
with increasing doses of AgNPs (1.25, 2.5 and 5 µg/mL, respectively) at 24 h in order to 
evaluate the effect of toxicity. The supernatant color indicates the release of hemoglobin from 
pRBCs and the pellet at the bottom of the 1.5 mL tubes corresponds to intact RBCs precipitated 
after centrifugation. The Hemolysis was evaluated by spectrophotometry at the fixed 
absorbance wavelength of 405 nm. Unlike the A. arborescens-AgNPs (1) that have 
demonstrated a significant haemolytic effect after 24 h of treatment (Figure 5A; 2.5 µg/mL p 
< 0.01; 5 µg/mL p < 0.001), the A. annua-AgNPs (1) have shown a dose-dependent haemolytic 
effect (Figure 5A; 2.5 µg/mL p < 0.05; 5 µg/mL p < 0.001), compared to the negative control. 
Results evidenced that pRBCs treated with low concentrations of Artemisia-AgNPs 
demonstrated good hemocompatibilty displaying low hemolysis after 24 h. (Figure 5B). The 
different hemolysis effect could be assigned to the difference in the size of nanoparticles.  
In fact, it has been reported that the variety of shape, size and chemistries of nanoparticles 
produce different effects on the biological environment.43 
 
Figure 5. Hemo-biocompatibility assays on human RBCs. A) Hemolysis assay on human pRBCs (PA strain) 
with increasing doses (1.25, 2.5, and 5 μg/mL) of “green” nanoparticles treated for 24 h. A) Samples were analysed 
by spectrophotometer. The hemolysis value is reported in Absorbance (405 nm). B) Pictures of human pRBCs at 
the different doses and time points. RBCs is the negative (-) and DDW the positive (+) control. 
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Growth inhibition of parasite P. falciparum by A. annua-AgNPs  
To further evaluate the effects on parasite maturation and death, a morphology investigation 
was performed on PA strain. PA culture was treated with increasing doses of nanoparticles 
(1.25, 2.5 and 5 µg/mL) at 24 h in order to evaluate the effect of parasite growth inhibition. A. 
annua-AgNPs (1) and (2) have demonstrated significant in vitro activity against P. falciparum 
in pRBCs, showing a decrease of parassitemia (Figure 6A) compared to AgNPs (3) and (4), 
synthesized through a classical chemical approach. Following the data results, it was decided 
to assess the next experiments using the intermediate dosage of nanoparticles (2.5 μg/mL). The 
IC50, IC90, IC99 values determined at 24 h using 2.5 μg/mL of nanoparticle dose display the best 
antiplasmodial activity played by A. annua-AgNPs (1) (Figure 6B).  
 
 
Figure 6. Antiplasmodium effect of nanoparticles. A) Percentage of parasitemia on PA strain treated for 24 h 
with increasing doses (1.25, 2.5, and 5 μg/mL) of nanoparticles. B) IC50, IC90, IC99 values determined at 24 h using 
2.5 μg/mL of nanoparticles dose response. 
 
Unlike the A. arborescens-AgNPs (1) that have demonstrated haemolytic effect after 24 h of 
treatment (Figure 5), the A. annua-AgNPs (2) have shown antiplasmodial activity by blocking 
the parasite maturation stage from trophozoite to rings (Figure 7).  
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Instead, A. annua-AgNPs (1) have shown a dose-dependent haemolytic effect (Figure 5) 
connected to the parasite death (Figure 7).  
 
 
Figure 7. Nanoparticles effect on parasite maturation. The morphology of pRBCs and parasite stage was 
determined in PA strain treated with the intermediate dose of nanoparticles (2.5 μg/mL) after 24 h. 
 
The striking morphological alteration observed in fixed blood smears of PA strain treated with  
A. arborescens-AgNPs (1) is linked to the small size and the different molecules in the two 
Artemisia extracts involved in the capping of the nanoparticles. Unlike the “classical” AgNPs, 
the “green” nanoparticles show a dose-dependent antiparasitic activity as reported in Figure 6 
and an antimalarial effect based on their size and surface capping. Furthermore, A. arborescens-
AgNPs (1) appear to be more haemolytic and reactive than the A. annua-AgNP (1) and (2), 
because of their smaller size and A. arborescens capping, compared to A. annua capping. 
 
5.4 Conclusions 
This work is based on the synthesis and characterization of different types of silver 
nanoparticles (AgNPs-) using a “green synthesis” approach. Data results have demonstrated 
that Artemisia extracts derived from A. annua and A. arborescens plants can be used to create 
a bio-capping on the AgNPs useful to modulate their biological activity.  
 Elisabetta Avitabile, Nanotechnology: development of nanotools to counteract human diseases,  
Tesi di dottorato in Life Sciences and Biotechnologies, Università degli Studi di Sassari. 
85 
This type of “green” nanoparticles has demonstrated an antiplasmodium activity in in vitro 
experiments against P. falciparum malaria parasite. The present work was performed as a pilot 
study in order to evaluate the nanoparticles potential antimalarial efficacy in parasitized human 
red blood cell and to understand their efficacy against P. falciparum as a new nanotool against 
malaria.  
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Chapter 6. General conclusions  
The recent advances in technology have led to the application of nanotechnology in medicine, 
starting a new discipline called nanomedicine. Nanotechnology represents a new field of 
science focused on the use of nanomaterials for enhancing detection, treatment and diagnosis 
of pathologies through the development of new nanotools. The present research work reviewed 
the applications of nanotechnology in the field of nanomedicine in order to shed light on the 
possibility of using innovative nanomaterials as future therapeutic agents. The aim is to present 
new nanoscale solutions to develop nanoagents able to counteract serious problems related to 
human health. Thus, breast cancer, bone loss dysfunction and malaria have been taken into 
consideration as they represent three of the most studied human diseases in the recent years.  
In the field of cancer therapy, the major potential of nanotechnology includes the ability to 
engineer nanovehicles with multiple molecules that, because of their small size, can penetrate 
tumors with a high specificity, therefore with significantly less side effects. The first phase of 
this work has been focused on the review of the literature about the main nanomaterials used in 
nanotechnology against breast cancer, because it represents the second most common form of 
neoplasia afflicting women all over the world. In particular, a deep overview has been provided 
on nanomaterials that have been so far investigated for the fight against BC, analysing all 
publications presented in the literature in the last nine years. In general, analysing the last 
decade of literature, the most nanomaterials studied to counteract breast cancer are the metal-
nanoparticles. Moreover, it has been put in relation the major nanoparticles which have been 
engineered to generate heat upon activation and lead to tumor cell destruction in non-invasive 
cancer therapy. Moreover, the review has been focused on theranostic materials for human 
applications, to inhibit tumor growth and realize the benefits for patients. The goal of this state 
of the art is to provide a useful guide depicting how nanotechnology can be used to overcome 
current barriers in breast cancer clinical practice, and how it will shape the future scenario of 
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breast cancer treatment, prevention and diagnosis i.e. reducing suffering related to 
chemotherapy and revolutionizing the current surgical approaches. Furthermore, the aim of the 
work is to inform the whole nanoscience-nanomedicine community on the research and latest 
advances on the nanotech BC -related field.  
Instead, in the context of bone loss diseases, the nanotechnology is used to develop a wide 
variety of nanotools to counteract the bone loss dysregulation. It has been reported that human 
spaceflights lead to the dysregulation of the osteoblast functions like an osteoporosis like 
conditions that are ordinarily connected to a normal bone resorption. In this context, the 
nanotechnology applications in the field of bone regeneration are focused on the development 
of nanomaterials able to counteract the osteoblastic dysfunction. Following this scenario, the 
attention of the second study has been focused on the role of nanotechnology on bone loss 
dysregulation. The aim was to evaluate the osteoinductive potential of induced human stem 
cells cultured in nano-scaffolds to promote osteogenic differentiation under microgravity 
simulation. Finally, during the last years, metal nanoparticles have been raising increasing 
interest in the scientific community due to their chemical stability, good conductivity and 
biological activity. In this context, silver nanoparticles (AgNPs) could represent new nanotools 
for biomedical applications thanks to their promising properties and their efficient anti-
inflammatory and antibacterial activity. Thus, the purpose of the last study was to focus the 
attention on metal nanoparticles to counteract malaria disease. In particular, silver nanoparticles 
have been synthetized in order to investigate their antiparasitic activity against P. falciparum 
using a novel green synthesis approach. 
In general, the results obtained have shown that the use of structures acting on the nanoscale 
allow to overcome some limitations found in conventional agents, showing promising results 
for the development of future alternative therapeutic treatments against human diseases. The 
investigation of the effects of these nanomaterials in in vitro experiments has shown a good 
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stability and biocompatibility in the interaction with the different cells used. Despite 
nanomaterials have confirmed their good osteogenic potential and anti-plasmodium activity 
played in the nanoscale context, further investigations into specific interactions between 
nanomaterials and in vivo models are needed to confirm this hypothesis. Finally, the data 
collected in in vitro experiments open a new path for further studies aimed at investigating the 
potential of these nanomaterials as a possible new nanotechnological strategy in the fight 
against the serious human diseases considered and tissue regeneration. 
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